Clinical trials recruiting in Hasselt, Belgium

Phase breakdown

Conditions recruiting in Hasselt, Belgium

Recruiting trials in Hasselt, Belgium

• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  NCT06966700 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
  NCT06742723 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
  NCT06996782 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter
  NCT07116525 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
  NCT07005128 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
  NCT06793215 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
  NCT05789082 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
  NCT06875310 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
  NCT07230691 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
  NCT06492616 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
  NCT07321886 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
  NCT06203210 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
  NCT07241390 · Phase: Phase 3 · Ages: 50 Years and older · Sex: All (male and female)
• A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
  NCT06623422 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
  NCT06312176 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
  NCT07174336 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
  NCT07218146 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
  NCT07155187 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
  NCT07005102 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in Belgium
  NCT07382440 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  NCT04928846 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
  NCT06126224 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
  NCT06819878 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
  NCT06561386 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
  NCT05894239 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  NCT06417814 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
  NCT07144280 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation
  NCT07625215 · Phase: Phase 2 · Ages: 18 Years to 85 Years · Sex: All (male and female)
• A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
  NCT06424288 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Accelerated Pacing and Cardiac Filling Pressures During Exercise in Patients With Heart Failure With Preserved Ejection Fraction
  NCT07270536 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer
  NCT06365788 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female
• CellFX® Nanosecond Pulsed Field Ablation (PFA) 360 Catheter Ablation System for Treatment of Atrial Fibrillation
  NCT06696170 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation
  NCT06784466 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 80 Years · Sex: All (male and female)
• Comparison of Conventional and Cooled Radiofrequency of the Genicular Nerves in Patients With Chronic Knee Pain
  NCT05407610 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• DESTINY Breast Respond HER2-(Ultra)Low Europe
  NCT05945732 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Determining the Extent of the Genitourinary Syndrome of Menopause Burden in Breast Cancer Survivors
  NCT07563621 · Phase: Not specified · Ages: 18 Years and older · Sex: Female
• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
  NCT07064473 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer
  NCT06831955 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• LimPrOn: Limburg Pre-eclampsia Investigation
  NCT03509272 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 50 Years · Sex: Female
• MYTHS - MYocarditis THerapy With Steroids
  NCT05150704 · Phase: Phase 3 · Ages: 18 Years to 69 Years · Sex: All (male and female)
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
  NCT07037459 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female)
• Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation
  NCT05955365 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
  NCT05980949 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• Performance After Cardiac Ablation in Endurance Athletes for Atrial Fibrillation
  NCT07726056 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 80 Years · Sex: All (male and female)
• Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
  NCT04613596 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
  NCT06757634 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
  NCT07291037 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
  NCT06357533 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Photobiomodulation Therapy for the Management of Breast Cancer-related Lymphedema
  NCT04690439 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female
• Physical Activity Coaching After Surgery for Patients With Resectable Non-small Cell Lung Cancer
  NCT06057766 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)
  NCT06784791 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy
  NCT05169593 · Phase: Phase 4 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
  NCT03903835 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• Prospective Athlete's Heart Study
  NCT05164328 · Phase: Not specified · Ages: 14 Years to 23 Years · Sex: All (male and female)
• PulseSelect™ PFA Global Registry
  NCT06393920 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
  NCT07413939 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Salvage Stereotactic Body Radiotherapy of the Prostate Bed for Biochemical Recurrence After Radical Prostatectomy.
  NCT06523634 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male
• Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure Prophylaxis
  NCT07029152 · Phase: Not applicable (e.g. observational or device study) · Ages: 35 Years and older · Sex: Male
• Stereotactic Body Radiation Therapy for Inoperable Non-metastasized Pancreatic Adenocarcinoma
  NCT06691425 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Structural Characteristics of Trunk and Limb Muscles in Cachectic Colorectal Cancer Patients
  NCT06780423 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Structured Testing and Treatment for Obstructive Sleep Apnea in Patients With Atrial Fibrillation
  NCT06263608 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
  NCT06801834 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
  NCT05633654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
  NCT06772623 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Supramaximal High-Intensity Interval Training in People With and Without Chronic Obstructive Pulmonary Disease
  NCT06068322 · Phase: Not applicable (e.g. observational or device study) · Ages: 60 Years and older · Sex: All (male and female)
• The Effect of Exercise on the Brain in Type 2 Diabetes
  NCT06734546 · Phase: Not applicable (e.g. observational or device study) · Ages: 30 Years to 75 Years · Sex: All (male and female)
• The Impact of Physical Activity Versus Dietary Energy Restriction on Tumour and Muscle Protein Synthesis in Prostate Cancer Patients
  NCT06406803 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male
• The RECLAIM Study.
  NCT06450444 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 84 Years · Sex: All (male and female)
• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
  NCT07028853 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
  NCT06472245 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
  NCT07181109 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Hasselt, Belgium?

71 recruiting trials have at least one study site in Hasselt, Belgium.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.